Interactions between Primaquine and Psyllium/senna

Primaquine has a major potential interaction with Anemia.

The use of primaquine is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. Primaquine has been reported to cause hematologic toxicity such as bone marrow depression, anemia, and leukopenia. Therapy with primaquine should be administered cautiously in patients with preexisting bone marrow depression or leukopenia. Since large doses of primaquine may increase the risk of leukopenia, the recommended dosage (15 mg base daily for 14 days in adults) should not be exceeded. Close monitoring is recommended if primaquine is prescribed to patients who have shown a previous idiosyncrasy to primaquine as manifested by leukopenia, hemolytic anemia, or methemoglobinemia. Blood cell counts should be performed regularly. Primaquine therapy should be discontinued immediately if there is a sudden decrease in leukocyte count.

The senna in psyllium/senna has a major potential interaction with Appendicitis.

The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis. These patients may be candidates for emergency surgery. Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.

The senna in psyllium/senna has a major potential interaction with Bleeding Disorder.

The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures. These preparations may cause irritation, burning sensation, and proctitis.

Primaquine has a major potential interaction with G-6-PD Deficiency.

Hemolysis, hemolytic anemia, and methemoglobinemia have been reported during use of primaquine in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency or nicotinamide adenine dinucleotide (NADH)-methemoglobin reductase deficiency. Therapy with primaquine should be administered cautiously in these patients. Since large doses of primaquine may increase the risk of hemolytic reactions, the recommended dosage (15 mg base daily for 14 days in adults) should not be exceeded. Close monitoring is recommended if primaquine is prescribed to patients who have shown a previous idiosyncrasy to primaquine or that have family or personal history of favism. Blood cell counts and hemoglobin determinations should be performed regularly. Primaquine therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.

The psyllium and senna in psyllium/senna both have a major potential interaction with Gastrointestinal Obstruction.

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

The psyllium in psyllium/senna has a major potential interaction with Gastrointestinal Obstruction.

The use of bulk producing laxatives is contraindicated in patients with intestinal obstruction or fecal impaction. Bulk producing laxatives can exacerbate these conditions.

The psyllium and senna in psyllium/senna both have a major potential interaction with Inflammatory Bowel Disease.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

Primaquine has a major potential interaction with Lupus Erythematosus.

The use of primaquine is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. Primaquine has been reported to cause hematologic toxicity such as bone marrow depression, anemia, and leukopenia. Therapy with primaquine should be administered cautiously in patients with preexisting bone marrow depression or leukopenia. Since large doses of primaquine may increase the risk of leukopenia, the recommended dosage (15 mg base daily for 14 days in adults) should not be exceeded. Close monitoring is recommended if primaquine is prescribed to patients who have shown a previous idiosyncrasy to primaquine as manifested by leukopenia, hemolytic anemia, or methemoglobinemia. Blood cell counts should be performed regularly. Primaquine therapy should be discontinued immediately if there is a sudden decrease in leukocyte count.

Primaquine has a major potential interaction with Methemoglobinemia.

Hemolysis, hemolytic anemia, and methemoglobinemia have been reported during use of primaquine in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency or nicotinamide adenine dinucleotide (NADH)-methemoglobin reductase deficiency. Therapy with primaquine should be administered cautiously in these patients. Since large doses of primaquine may increase the risk of hemolytic reactions, the recommended dosage (15 mg base daily for 14 days in adults) should not be exceeded. Close monitoring is recommended if primaquine is prescribed to patients who have shown a previous idiosyncrasy to primaquine or that have family or personal history of favism. Blood cell counts and hemoglobin determinations should be performed regularly. Primaquine therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.

Primaquine has a major potential interaction with Neutropenia.

The use of primaquine is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. Primaquine has been reported to cause hematologic toxicity such as bone marrow depression, anemia, and leukopenia. Therapy with primaquine should be administered cautiously in patients with preexisting bone marrow depression or leukopenia. Since large doses of primaquine may increase the risk of leukopenia, the recommended dosage (15 mg base daily for 14 days in adults) should not be exceeded. Close monitoring is recommended if primaquine is prescribed to patients who have shown a previous idiosyncrasy to primaquine as manifested by leukopenia, hemolytic anemia, or methemoglobinemia. Blood cell counts should be performed regularly. Primaquine therapy should be discontinued immediately if there is a sudden decrease in leukocyte count.

The psyllium in psyllium/senna has a moderate potential interaction with Renal Dysfunction.

Bulk producing laxatives require the consumption of at least 8 ounces of fluid per each dose. Patients with fluid restriction conditions such as renal dysfunction may benefit more from emollient or stimulant laxatives.

Primaquine has a major potential interaction with Rheumatoid Arthritis.

The use of primaquine is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. Primaquine has been reported to cause hematologic toxicity such as bone marrow depression, anemia, and leukopenia. Therapy with primaquine should be administered cautiously in patients with preexisting bone marrow depression or leukopenia. Since large doses of primaquine may increase the risk of leukopenia, the recommended dosage (15 mg base daily for 14 days in adults) should not be exceeded. Close monitoring is recommended if primaquine is prescribed to patients who have shown a previous idiosyncrasy to primaquine as manifested by leukopenia, hemolytic anemia, or methemoglobinemia. Blood cell counts should be performed regularly. Primaquine therapy should be discontinued immediately if there is a sudden decrease in leukocyte count.